Therapy News and Research

RSS

WSJ investigation: A sharp rise in specific prostate therapy parallels high Medicare payments

Roughly one in three Medicare beneficiaries diagnosed with prostate cancer today gets a sophisticated form of radiation therapy called IMRT. …The story behind the sharp rise in the use of IMRT — which stands for intensity-modulated radiation therapy — is about more than just the rapid adoption of a new medical technology.

9 Dec 2010

Study demonstrates new test for early diagnosis of Turner syndrome

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) has demonstrated a novel and accurate test for early diagnosis of Turner syndrome. Turner syndrome affects one in 1,500 to 2,000 female live births and early diagnosis allows for the timely management of short stature and co-morbid conditions including cardiac and renal problems.

9 Dec 2010

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.

9 Dec 2010

European researchers develop new form of therapy for Alpha-mannosidosis

Alpha-mannosidosis is a rare childhood disease which causes symptoms such as mental retardation or hearing loss and is linked to a lower life expectancy. A European research team headed by Professor Paul Saftig from Christian-Albrechts-Universit-t zu Kiel has developed a form of therapy as part of the Alpha-Man project, which will receive around six million euros from the European Union for its next stage of trials.

9 Dec 2010

p53 activation offers a novel strategy for cancer therapy

A pioneering clinical trial is testing the effectiveness in leukemia of a small molecule that shuts down MDM2, a protein that can disable the well-known tumor suppressor p53.

9 Dec 2010

Texas leaders cut spending for Medicaid, Wyo. begins to set up state exchange

"State leaders, trying to dig out of a hole in the current two-year budget before the next one has to be whacked, ordered agencies Tuesday to further curb spending. Agency chiefs were told in a letter that they must reduce expenditures by 2.5% in the remaining nine months of the fiscal year. Managers of the state Medicaid program immediately announced they would cut another 1% from the fees paid to doctors, dentists and hospitals, along with 2% in payments to nursing homes and home health care providers. The decreases take effect Feb. 1, and they come on top of 1% cuts that kicked in just before Labor Day" (Garrett, 12/8).

9 Dec 2010

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.

9 Dec 2010

New technique jumpstarts growth of nerve fibers to reverse stroke damage

A new technique that jumpstarts the growth of nerve fibers could reverse much of the damage caused by strokes, researchers report in the Jan. 7, 2011 issue of the journal Stroke.

9 Dec 2010

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Anchor Therapeutics today announced the publication of new research in the Proceedings of the National Academy of Sciences USA. The paper describes the identification and characterization of a pepducin-based allosteric agonist that targets CXCR4, a chemokine G protein-coupled receptor found on hematopoietic stem cells and other bone marrow-derived cells.

9 Dec 2010

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

Celgene International Sàrl today announced that its next IMiD compound, pomalidomide, was evaluated in three separate investigational trials of patients with multiple myeloma who were relapsed or refractory after prior treatments including lenalidomide, thalidomide and bortezomib. The clinical data were presented at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

9 Dec 2010

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

DPT Laboratories, Ltd., a pharmaceutical contract development and manufacturing organization, announced today that it received FDA approval to manufacture commercial supplies of a leading sterile ointment for wound care at its Center of Excellence for Sterile & Specialty Products in Lakewood, N.J. Beginning this month, Healthpoint will ship commercial lots of Collagenase SANTYL® Ointment produced at DPT's Lakewood facility to its North American customers.

9 Dec 2010

Medulloblastoma subtypes are separate diseases with different origins

International effort led by St. Jude Children's Research Hospital scientists is expected to fuel development of targeted therapies and aid the search for unique combinations of cells and mutations that lead to other cancers.

8 Dec 2010

FDA clears Valeritas' V-Go Disposable Insulin Delivery Device

Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that the US Food and Drug Administration has cleared the company's V-Go Disposable Insulin Delivery Device for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin.

8 Dec 2010

First Edition: December 8, 2010

Today's health policy headlines include more detail on the deal reached to avoid a scheduled cut in physician's Medicare pay.

8 Dec 2010

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADE (bortezomib) in patients with relapsed multiple myeloma. These data were presented at the 52nd annual meeting of the American Society of Hematology, held December 4-7 in Orlando, Florida.

8 Dec 2010

Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone

Status epilepticus, prolonged seizures, can lead to significant neurological deficits and, rarely, even death. The anticonvulsant diazepam, a first line therapy for the condition, is neuroprotective when administered in high doses within two hours from seizure onset. Researchers at the 64th AES Annual Meeting now report that the combination of low-dose diazepam and NS-398, a COX-2 inhibitor, has twice the neuroprotective effect of NS-398 alone.

8 Dec 2010

St. Luke's Episcopal Hospital, UH College of Pharmacy earn national 'best practices' award

With antibiotic resistance on the rise worldwide, health care professionals are continually seeking to optimize how they combat drug-resistant infections.

8 Dec 2010

Novel therapy against hepatitis C disease

University of Maryland School of Pharmacy researchers have developed a mathematical model for choosing an appropriate dosage of the hepatitis medications for individual patients. The work helps explain why African American patients tend to not respond as well to the drugs as other patients.

8 Dec 2010

New approach points towards effective stem cell therapies for spinal cord injury

Initial experiments suggest a possible new approach to stem cell therapy for spinal cord injuries—using biocompatible "channels" made of chitosan to guide regeneration of new spinal cord tissue, reports the December issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

8 Dec 2010

Sleep deprivation eliminates fear-associated memories

We commonly think of sleep as a healing process that melts away the stresses of the day, preparing us to deal with new challenges. Research has also shown that sleep plays a crucial role in the development of memories.

8 Dec 2010

Therapy News and Research

WSJ investigation: A sharp rise in specific prostate therapy parallels high Medicare payments

Study demonstrates new test for early diagnosis of Turner syndrome

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

European researchers develop new form of therapy for Alpha-mannosidosis

p53 activation offers a novel strategy for cancer therapy

Texas leaders cut spending for Medicaid, Wyo. begins to set up state exchange

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

New technique jumpstarts growth of nerve fibers to reverse stroke damage

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

Medulloblastoma subtypes are separate diseases with different origins

FDA clears Valeritas' V-Go Disposable Insulin Delivery Device

First Edition: December 8, 2010

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone

St. Luke's Episcopal Hospital, UH College of Pharmacy earn national 'best practices' award

Novel therapy against hepatitis C disease

New approach points towards effective stem cell therapies for spinal cord injury

Sleep deprivation eliminates fear-associated memories

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News